---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000029"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:29:12.024771+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand reports Q1 revenue $31M; net income $86.1M on Viking gain; reaffirms guidance; $100M Agenus royalty deal

## Summary
- Q1 total revenue $31.0M vs $44.0M last year; royalties up $19.1M from $17.6M.
- Net income $86.1M ($4.75 diluted) vs $43.6M, includes $60M realized gain on Viking stock.
- Core adjusted EPS $1.20 vs $1.33; decrease due to prior-year $15.3M Travere milestone.
- Reaffirms 2024 guidance: total revenue $130-142M, core adjusted EPS $4.25-4.75.
- Entered $100M royalty financing with Agenus for six partnered oncology programs; $75M upfront.

## SEC filing metadata
- accession: 0000886163-24-000029
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/lgnd-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000029
- JSON: https://secwatch.observer/filing/0000886163-24-000029.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000029.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported 2024 results: revenue $130 million to $142 million, EPS approximately $4.25 to $4.75. Guidance reaffirmed.
  - Period: 2024
  - Revenue: $130 million to $142 million
  - EPS: approximately $4.25 to $4.75
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Ligand is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million. Ligand notes that with total revenue of $130 million to $142 million, core adjusted earnings per diluted share are expected to range from approximately $4.25 to $4.75.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $31.0 million, net income $86.1 million, EPS $4.75 per diluted share.
  - Period: the three months ended March 31, 2024
  - Revenue: $31.0 million
  - Net income: $86.1 million
  - EPS: $4.75 per diluted share
  - Result: reported results
  source text: Total revenues and other income for the first quarter of 2024 were $31.0 million, compared with $44.0 million for the same period in 2023. Royalties for the first quarter of 2024 were $19.1 million, compared with $17.6 million for the same period in 2023, with the increase primarily attributable to Amgen’s (Nasdaq: AMGN) Kyprolis, Jazz Pharmaceuticals' (Nasdaq: JAZZ) RYLAZE, Merck and Co.’s (NYSE: MRK) VAXNEUVANCE and Travere Therapeutics’ (Nasdaq: TVTX) FILSPARI, partially offset by a decline in CASI’s (Nasdaq: CASI) EVOMELA. Captisol sales were $9.2 million for the first quarter of 2024, compared with $10.6 million for the same period in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024, compared with $15.7 million for the same period in 2023, with the difference driven by a $15.3 million milestone payment earned from Travere Therapeutics upon the FDA approval of FILSPARI in the prior year quar
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.